DYN Stock Analysis: Dyne Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.936m USD | 12M Return: -29.1% | US26818M1080 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 43.6M
Qual. Beats: -1
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Dyne Therapeutics is a clinical-stage biotechnology company developing treatments for serious neuromuscular diseases. Its pipeline targets myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD), and Pompe disease, along with other rare skeletal, cardiac, and metabolic muscle conditions. The companys work is built around its proprietary FORCE platform, which is designed to deliver disease-modifying therapeutics directly to muscle tissue.
Founded in 2017 and headquartered in Waltham, Massachusetts, Dyne operates in the rare disease segment of the biotechnology industry, an area that often benefits from regulatory pathways such as orphan drug designation. As a clinical-stage company, it has not yet commercialized any products and its value is largely tied to the progression of its drug candidates through clinical trials and partnerships with larger pharmaceutical companies.
- DM1 therapy DYNE-101 phase trial data readout approaches
- DMD program DYNE-251 competes in Sarepta-dominated exon-skipping market
- Cash burn and dilution risk as clinical-stage biotech with no revenue
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.49 > 0.02 and ΔFCF/TA 1.71 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.48 > 3% & CFO -477.8m > Net Income -519.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 12.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (165.5m) vs 12m ago 45.29% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.22%; Δ -0.22% > 0%) |
| Interest Coverage Ratio: -33.40 > 6 (EBIT TTM -497.5m / Interest Expense TTM 14.9m) |
| A: 0.87 (Total Current Assets 937.9m - Total Current Liabilities 78.0m) / Total Assets 994.0m |
| B: -1.71 (Retained Earnings -1.70b / Total Assets 994.0m) |
| C: -0.58 (EBIT TTM -497.5m / Avg Total Assets 861.5m) |
| D: 2.41 (Book Value of Equity 702.2m / Total Liabilities 291.9m) |
| Altman-Z'' = -1.24 = CCC |
As of November 01, 2026, the stock is trading at USD 16.69 with a total of 1,449,801 shares traded. Over the past week, the price has changed by +6.85%, over one month by +2.96%, over three months by -35.13% and over the past year by -29.13%.
Current recommended Stop Loss: 15.60 (which is 6.5% or 1.2 ATR below the current price).
Dyne Therapeutics has received a consensus analysts rating of 4.65. Therefore, it is recommended to buy DYN.
- StrongBuy: 13
- Buy: 3
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 35.7 | 114.1% |
P/B = 4.1517
P/EG = 0.19
Revenue TTM = 0.0 USD
EBIT TTM = -497.5m USD
EBITDA TTM = -495.3m USD
Long Term Debt = 199.3m USD (from longTermDebt, last quarter)
Short Term Debt = 5.37m USD (from shortTermDebt, last quarter)
Debt = 224.6m USD (corrected: LT Debt 199.3m + ST Debt 5.37m) + Leases 19.9m
Net Debt = -497.5m USD (calculated: Debt 224.6m - CCE 722.0m)
Enterprise Value = 2.44b USD (2.94b + Debt 224.6m - CCE 722.0m)
Interest Coverage Ratio = -33.40 (Ebit TTM -497.5m / Interest Expense TTM 14.9m)
EV/FCF = -4.99x (Enterprise Value 2.44b / FCF TTM -488.3m)
FCF Yield = -20.03% (FCF TTM -488.3m / Enterprise Value 2.44b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 2.05m) / Revenue TTM)
Tobins Q-Ratio = 2.45 (Enterprise Value 2.44b / Total Assets 994.0m)
Interest Expense / Debt = 6.63% (Interest Expense 14.9m / Debt 224.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -393.0m (EBIT -497.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.40 (Total Current Assets 937.9m / Total Current Liabilities 90.2m)
Debt / Equity = 0.32 (Debt 224.6m / totalStockholderEquity, last quarter 702.2m)
Debt / EBITDA = 1.00 (negative EBITDA) (Net Debt -497.5m / EBITDA -495.3m)
Debt / FCF = 1.02 (negative FCF - burning cash) (Net Debt -497.5m / FCF TTM -488.3m)
Total Stockholder Equity = 807.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -60.29% (Net Income -519.4m / Total Assets 994.0m)
RoE = -64.30% (Net Income TTM -519.4m / Total Stockholder Equity 807.8m)
RoCE = -49.40% (EBIT -497.5m / Capital Employed (Equity 807.8m + L.T.Debt 199.3m))
RoIC = -42.66% (negative operating profit) (NOPAT -393.0m / Invested Capital 921.4m)
WACC = 10.80% (E(2.94b)/V(3.16b) * Re(11.23%) + D(224.6m)/V(3.16b) * Rd(6.63%) * (1-Tc(0.21)))
Discount Rate = 11.23% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.62 | Cagr: 37.33%
[DCF] Fair Price = unknown (Cash Flow -488.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -2.78 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.89 | Chg30d=+0.00% | Revisions=+0% | Analysts=14
EPS current Year (2026-12-31): EPS=-3.55 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=-2.3% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.34 | Chg30d=-0.09% | Revisions=+12% | GrowthEPS=+6.0% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +18% (up=5, down=3)